Key result
Proteinuric remission in diffuse proliferative lupus nephritis linked to ~79% lower composite outcome risk.
Why the study?
The prognostic importance of proteinuria for estimating outcomes in lupus nephritis requires verification.
Does proteinuric remission predict improved survival and renal outcomes in patients with diffuse proliferative lupus nephritis?
Cohort (n=193)
Does proteinuric remission predict improved survival and renal outcomes in patients with diffuse proliferative lupus nephritis?
Proteinuric remission is a strong independent predictor of improved survival and renal outcomes in patients with diffuse proliferative lupus nephritis.
Answers are grounded in this paper and cite their sources.
Proteinuric remission was associated with lower mortality and ESRD risk in lupus nephritis; hypothesis-generating for monitoring strategies pending prospective validation.
Proteinuria is a well-known risk factor for the progression of renal dysfunction in chronic kidney disease; however, its importance for estimating the prognosis of lupus nephritis requires verification. Korean adult patients with renal biopsy-diagnosed diffuse proliferative lupus nephritis who had undergone three or more consecutive urine protein to creatinine ratio or urine dipstick tests within six months after renal biopsy were enrolled. The cumulative risks, predictors, and outcomes of proteinuric remission and flare were evaluated. This study included 26 men and 167 women with a mean age at renal biopsy of 31.2 ± 9.8 years. Eighty-two (42.5%) patients experienced proteinuric remission during the follow-up period. During a mean follow-up of 157.9 ± 69.5 months, among patients who achieved proteinuric remission, one died, one developed end-stage renal disease (ESRD), and two had composite outcomes; among patients without remission, nine died, 24 developed ESRD, and 30 had composite outcomes. Patients who achieved proteinuric remission had a 0.089-fold risk (95% CI: 0.011-0.736) of mortality, 0.110-fold risk (95% CI: 0.013-0.904) of incident ESRD, and 0.210-fold risk (95% CI: 0.048-0.920) of a composite outcome compared to patients without remission. Among the 82 patients who achieved proteinuric remission, 59 (72.0%) experienced at least one proteinuria flare; however, relapse did not correlate with the incidence of outcomes. In conclusion, proteinuric remission is an independent predictive prognostic marker of good renal survival and mortality, regardless of the interval from biopsy to remission, recurrence of proteinuria after remission, renal function status at remission, or hematuria remission.
No takes yet. Share an insight, caveat, or question.
Koo et al. (2015) conducted a cohort in Diffuse proliferative lupus nephritis (n=193). Proteinuric remission vs. No proteinuric remission was evaluated on Composite outcome (RR 0.210, 95% CI 0.048-0.920). Proteinuric remission in patients with diffuse proliferative lupus nephritis was associated with a significantly lower risk of a composite outcome compared to no remission (RR 0.210; 95% CI 0.048-0.920).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: